FPF
PTCT icon

FNY Partners Fund’s PTC Therapeutics PTCT Stock Holding History

FNY Partners Fund’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50
Closed -$1K – 571
2017
Q3 		$1K Buy
+50
New +$979 ﹤0.01% 524

Other funds holding PTCT

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FNY Partners Fund's PTCT Position: Q1 2018 in Review

FNY Partners Fund opened a new position in PTC Therapeutics (PTCT) in Q1 2018: 1,354 shares worth $36K. The stake represents 0.02% of the portfolio and ranks #203 among its holdings. This is a return to the name: FNY Partners Fund previously reported a position in PTCT as recently as Q4 2016.

FNY Partners Fund first reported a position in PTCT in Q4 2016 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold PTCT as of Q1 2018.

  • FNY Partners Fund held 1,354 shares of PTC Therapeutics worth $36K as of Q1 2018.
  • PTC Therapeutics was a new FNY Partners Fund position in Q1 2018.
  • PTC Therapeutics made up 0.02% of FNY Partners Fund's portfolio in Q1 2018, its #203 holding.
  • FNY Partners Fund first reported a position in PTC Therapeutics in Q4 2016 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.